14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends
Carregando...
Citações na Scopus
273
Tipo de produção
article
Data de publicação
2014
Editora
ELSEVIER SCIENCE BV
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
ERKAN, Doruk
AGUIAR, Cassyanne L.
COHEN, Hannah
CUADRADO, Maria J.
DANOWSKI, Adriana
LEVY, Roger A.
ORTEL, Thomas L.
RAHMAN, Anisur
SALMON, Jane E.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
AUTOIMMUNITY REVIEWS, v.13, n.6, p.685-696, 2014
Resumo
Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The primary objective of the APS Treatment Trends Task Force, created as part of the 14th International Congress on aPL, was to systematically review the potential future treatment strategies for aPL-positive patients. The task force chose as future clinical research directions: a) determining the necessity for controlled clinical trials in venous thromboembolism with the new oral direct thrombin or anti-factor Xa inhibitors pending the results of the ongoing rivaroxaban in APS (RAPS) trial, and designing controlled clinical trials in other forms of thrombotic APS; b) systematically analyzing the literature as well as aPL/APS registries, and creating specific registries for non-warfarin/heparin anticoagulants; c) increasing recruitment for an ongoing primary thrombosis prevention trial, and designing secondary thrombosis and pregnancy morbidity prevention trials with hydroxychloroquine; d) determining surrogate markers to select patients for statin trials; e) designing controlled studies with rituximab and other and-B-cell agents; f) designing mechanistic and clinical studies with eculizumab and other complement inhibitors; and g) chemically modifying peptide therapy to improve the half-life and minimize immunogenicity. The report also includes recommendations for clinicians who consider using these agents in difficult-to-manage aPL-positive patients.
Palavras-chave
Antiphospholipid syndrome, Oral direct thrombin inhibitors, Hydroxychloroquine, Statins, Complement and B-cell inhibition, Peptide therapy
Referências
- Ageno W, 2013, J Thromb Haemost, V11, P177, DOI 10.1111/jth.12038
- Agmon-Levin N, 2011, ANN RHEUM DIS, V70, P145, DOI 10.1136/ard.2010.134817
- Agmon-Levin N, 2013, CLIN REV ALLERG IMMU, V45, P256, DOI 10.1007/s12016-012-8342-y
- Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507
- Aguiar CL, 2013, APLA LACA
- Akkerman A, 2004, AUTOIMMUNITY, V37, P445, DOI 10.1080/0891693040008524
- Ames PRJ, 2010, LUPUS, V19, P711, DOI 10.1177/0961203309357765
- Ames PRJ, 2007, ANN HEMATOL, V86, P227, DOI 10.1007/s00277-006-0226-x
- Andreoli L, 2012, LUPUS, V21, P736, DOI 10.1177/0961203312446386
- [Anonymous], 2011, LIX ED 15 MG 30 MG T
- [Anonymous], SUMM PROD CHAR SPC E
- Baglin T, 2012, BRIT J HAEMATOL, V159, P427, DOI 10.1111/bjh.12052
- EINSTEIN Investigators, 2010, N Engl J Med, V363, P2499, DOI 10.1056/NEJMoa1007903
- Berman H, 2013, AUTOIMMUN REV, V12, P1085, DOI 10.1016/j.autrev.2013.05.004
- Blank M, 1999, P NATL ACAD SCI USA, V96, P5164, DOI 10.1073/pnas.96.9.5164
- Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166
- Broder A, 2013, J RHEUMATOL, V40, P30, DOI 10.3899/jrheum.120157
- Broder A, 2009, ARTHRITIS RHEUM S10, V60, P279
- Bulla R, 2005, CHEM IMMUNOL ALLERGY, V89, P149
- Buller HR, 2012, NEW ENGL J MED, V366, P1287
- Castellone DD, 2010, AM J HEMATOL, V85, P185, DOI 10.1002/ajh.21607
- Costa Rubens, 2013, Clin Rheumatol, V32 Suppl 1, pS79, DOI 10.1007/s10067-010-1506-3
- Costedoat-Chalumeau N, 2007, ANN RHEUM DIS, V66, P821, DOI 10.1136/ard.2006.067835
- Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/ke1402
- Cuadrado MJ, 1997, ARTHRITIS RHEUM, V40, P834, DOI 10.1002/art.1780400509
- Danesh FR, 2003, ARCH IMMUNOL THER EX, V51, P139
- de la Torre YM, 2012, J AUTOIMMUN, V38, pJ209, DOI 10.1016/j.jaut.2011.11.009
- de Leeuw K, 2006, LUPUS, V15, P675, DOI 10.1177/0961203306069972
- DeZern AE, 2013, EUR J HAEMATOL, V90, P16, DOI 10.1111/ejh.12021
- Edwards MH, 1997, CIRCULATION, V96, P4380
- Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
- Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
- Elalamy I, 2008, J THROMB HAEMOST, V6, P1242, DOI 10.1111/j.1538-7836.2008.02973.x
- Erdozain J G, 2004, Haematologica, V89, pECR34
- Erkan D, 2013, ANN RHEUM DIS
- Erkan D, 2002, RHEUMATOLOGY, V41, P924, DOI 10.1093/rheumatology/41.8.924
- Erkan D, 2005, ANN RHEUM DIS, V64, P1321, DOI 10.1136/ard.2004.031856
- Erkan D, 2013, ARTHRITIS RHEUM-US, V65, P464, DOI 10.1002/art.37759
- Erre GL, 2008, LUPUS, V17, P50, DOI 10.1177/0961203307085251
- Ferrara DE, 2004, J THROMB HAEMOST, V2, P1558, DOI 10.1111/j.1538-7836.2004.00896.x
- Ferrara DE, 2003, ARTHRITIS RHEUM, V48, P3272, DOI 10.1002/art.11449
- Fleisher LA, 2008, ANESTH ANALG, V106, P685, DOI 10.1213/01/ane.0000309024.28586.70
- Frances C, 2012, ARCH DERMATOL, V148, P479, DOI 10.1001/archdermatol.2011.2558
- Gharavi AE, 2003, LUPUS, V12, P579, DOI 10.1191/0961203303lu448rr
- Gharavi AE, 2002, ARTHRITIS RHEUM, V46, P545, DOI 10.1002/art.10130
- Giannakopoulos B, 2007, BLOOD, V109, P422, DOI 10.1182/blood-2006-04-001206
- Girardi G, 2003, J CLIN INVEST, V112, P1644, DOI 10.1172/JCI18817
- Girardi G, 2004, NAT MED, V10, P1222, DOI 10.1038/1121
- Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241
- Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688
- Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
- Hindler K, 2006, ANESTHESIOLOGY, V105, P1260, DOI 10.1097/00000542-200612000-00027
- Ho KT, 2005, RHEUMATOLOGY, V44, P1303, DOI 10.1093/rheumatology/kei014
- Holtan SG, 2006, J THROMB HAEMOST, V4, P1632, DOI 10.1111/j.1538-7836.2006.01961.x
- Huang HC, 2010, P NATL ACAD SCI USA, V107, P4658, DOI 10.1073/pnas.1001074107
- HUNT J, 1994, J IMMUNOL, V152, P653
- Ioannou Y, 2007, ARTHRITIS RHEUM-US, V56, P280, DOI 10.1002/ary.22306
- Ioannou Y, 2009, J THROMB HAEMOST, V7, P833, DOI 10.1111/j.1538-7836.2009.03316.x
- Iverson GM, 2002, J IMMUNOL, V169, P7097
- Iverson GM, 1998, P NATL ACAD SCI USA, V95, P15542, DOI 10.1073/pnas.95.26.15542
- JOHNSON R, 1979, CLIN ORTHOP RELAT R, P174
- Jung HJ, 2010, ARTHRITIS RHEUM-US, V62, P863, DOI 10.1002/art.27289
- Kahn P, 2008, ARTHRITIS RHEUM, V58, P2824, DOI 10.1002/art.23764
- Kaiser R, 2009, ANN RHEUM DIS, V68, P238, DOI 10.1136/ard.2008.093013
- Khattri S, 2012, AUTOIMMUN REV, V11, P717, DOI 10.1016/j.autrev.2011.12.011
- Khianey R, 2013, APLA LACA
- Klack K, 2010, JOINT BONE SPINE, V77, P489, DOI 10.1016/j.jbspin.2010.02.043
- Kumar Deepak, 2010, Curr Rheumatol Rep, V12, P40, DOI 10.1007/s11926-009-0074-5
- Lauvao LS, 2008, J VASC SURG, V48, P472, DOI 10.1016/j.jvs.2008.02.052
- Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
- Levine AB, 2012, ACR
- Linkins LA, 2012, CHEST S, V141, pe495S
- Lockshin MD, 2010, J REPROD IMMUNOL, V84, P206, DOI 10.1016/j.jri.2009.11.007
- Lonze BE, 2010, NEW ENGL J MED, V362, P1744, DOI 10.1056/NEJMc0910965
- Lopez-Pedrera C, 2011, ANN RHEUM DIS, V70, P675, DOI 10.1136/ard.2010.135525
- Majka DS, 2013, INFLAMM RES, V62, P919, DOI 10.1007/s00011-013-0652-x
- Marmor MF, 2011, OPHTHALMOLOGY, V118, P415, DOI 10.1016/j.ophtha.2010.11.017
- Martinez-Martinez LA, 2007, CLIN EXP RHEUMATOL, V25, P18
- Martinuzzo ME, 2013, INT J LAB HEMATOL
- Medina G, 2011, AUTOIMMUN REV, V10, P214, DOI 10.1016/j.autrev.2010.10.004
- Meroni PL, 2001, ARTHRITIS RHEUM, V44, P2870, DOI 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y
- Merriman E, 2011, THROMB HAEMOSTASIS, V105, P385, DOI 10.1160/TH10-08-0511
- Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
- Mok CC, 2005, ARTHRITIS RHEUM, V52, P2774, DOI 10.1002/art.21224
- Mok MY, 2005, J RHEUMATOL, V32, P622
- Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527
- Odiari EA, 2012, HUM REPROD, V27, P2933, DOI 10.1093/humrep/des288
- Ostertag MV, 2006, LUPUS, V15, P358, DOI 10.1191/0961203306lu2315oa
- Ota K, 2013, HUM REPROD
- Paupitz JA, 2010, LUPUS, V19, P1302, DOI 10.1177/0961203310372938
- Peerschke EI, 2010, MOL IMMUNOL, V47, P2170, DOI 10.1016/j.molimm.2010.05.009
- Pericleous C, 2011, MOL IMMUNOL, V49, P56, DOI 10.1016/j.molimm.2011.07.024
- Pericleous C, 2010, ARTHRITIS RHEUM, V62, pS563
- Petri M., 1994, Arthritis and Rheumatism, V37, pS297
- Petri M, 2013, APLA LACA
- Piantoni S, 2012, Reumatismo, V64, P307, DOI 10.4081/reumatismo.2012.307
- Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
- Pierangeli SS, 1999, CIRCULATION, V99, P1997
- Pierangeli SS, 2004, J AUTOIMMUN, V22, P217, DOI 10.1016/j/jaut.2004.01.002
- Rand JH, 2010, BLOOD, V115, P2292, DOI 10.1182/blood-2009-04-213520
- Rand JH, 2008, BLOOD, V112, P1687, DOI 10.1182/blood-2008-03-144204
- Redecha P, 2007, BLOOD, V110, P2423, DOI 10.1182/blood-2007-01-070631
- Redecha P, 2008, J CLIN INVEST, V118, P3453, DOI 10.1172/JCI36089
- Ridker PM, 2009, LANCET, V373, P1175, DOI 10.1016/S0140-6736(09)60447-5
- Ritis K, 2006, J IMMUNOL, V177, P4794
- Rota E, 2008, THROMB HAEMOSTASIS, V99, P779, DOI 10.1160/TH07-09-0573
- Rubenstein E, 2006, J RHEUMATOL, V33, P355
- Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
- Ruiz-Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
- Sacre K, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3895
- Salem M, 2010, THROMB HAEMOSTASIS, V104, P1071, DOI [10.1160/TH10-05-0284, 10.1160/TH10.05.0284]
- Salmon JE, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001013
- Samama MM, 2011, CLIN CHEM LAB MED, V49, P761, DOI 10.1515/CCLM.2011.134
- Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
- Schmidt-Tanguy A, 2013, J THROMB HAEMOST, V11, P1927, DOI 10.1111/jth.12363
- Schulman S, 2009, N ENGL MED, V361, P2341
- Sciascia S, 2011, LUPUS, V20, P1106, DOI 10.1177/0961203311400115
- Shapira I, 2012, ARTHRITIS RHEUM-US, V64, P2719, DOI 10.1002/art.34440
- Simantov E, 1995, J CLIN INVEST, V96, P2211
- Sinibaldi S, 2013, PEDIATR TRANSPLANT, V17, pE177, DOI 10.1111/petr.12151
- Stohl W, 2012, ARTHRITIS RHEUM-US, V64, P2328, DOI 10.1002/art.34400
- Summary of product characteristics (SPC), SUMM PROD CHAR SPC E
- Summary of product characteristics (SPC), 2011, SUMM PROD CHAR SPC E
- Summary of product characteristics (SPC), SUMM PROD CHAR SPC E
- Tektonidou MG, 2009, ARTHRIT RHEUM-ARTHR, V61, P29, DOI 10.1002/art.24232
- Tenedios F, 2005, ARTHRITIS RHEUM, V52, P4078
- Buller HR, 2013, NEW ENGL J MED, V369, P1406, DOI 10.1056/NEJMoa1306638
- Tommasino C, 2004, THROMB RES, V114, P652
- Trappe R, 2006, ANN HEMATOL, V85, P134, DOI 10.1007/s00277-005-0028-6
- Tripodi A, 2001, BRIT J HAEMATOL, V115, P672, DOI 10.1046/j.1365-2141.2001.03178.x
- Tsagalis G, 2011, ARTIF ORGANS, V35, P420, DOI 10.1111/j.1525-1594.2010.01068.x
- Urowitz MB, 2010, ARTHRIT CARE RES, V62, P881, DOI 10.1002/acr.20122
- Van Os GMA, 2011, J THROMB HAEMOST, V9, P1657, DOI 10.1111/j.1538-7836.2011.04395.x
- WALLACE DJ, 1987, ARTHRITIS RHEUM, V30, P1435, DOI 10.1002/art.1780301219
- Warkentin TE, 2008, J THROMB HAEMOST, V6, P1243, DOI 10.1111/j.1538-7836.2008.2972.x
- Warkentin TE, 2007, NEW ENGL J MED, V356, P2653
- Watson H, 2012, BRIT J HAEMATOL, V159, P528, DOI 10.1111/bjh.12059
- Wu XX, 2011, AM J OBSTET GYNECOL, V205, pe7
- Xu CG, 2000, SCIENCE, V287, P498, DOI 10.1126/science.287.5452.498
- Youinou P, 2004, THROMB RES, V114, P363, DOI 10.1016/j.thromres.2004.06.019